Keyword: Gardasil

CDC officials have been pushing HPV vaccination, and in 2017—just as in the previous four years—those efforts yielded only a slight increase.

Merck's HPV shot, Gardasil, continued to gain steam in the second quarter, and execs see "significant" growth prospects ahead.

Activists have railed at the U.K. government for refusing to offer Merck's HPV vaccine Gardasil to boys, but now the government has reversed its stance.

Here is some other vaccine news of note for the week.

Merck is seeking FDA approval to expand Gardasil 9's use in women and men ages 27 to 45.

GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.

Takeda investors voice concerns over Shire deal; WuXi AppTec becomes the largest-cap CRO; two families' wealth swells on Gardasil nods.

The chairman of Zhifei Biological Products, which holds Chinese rights to Gardasil and Gardasil 9, boasted a net worth of about $4.6 billion Wednesday.

A new study shows that when doctors were persistent in encouraging HPV vaccination, 94% of children were vaccinated.

Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.